Quantcast
Last updated on April 17, 2014 at 16:43 EDT

Innocutis Announces the FDA Approval of Nuvail(TM) (Poly-Ureaurethane, 16%) for the Treatment of Nail Dystrophy

September 18, 2012

CHARLESTON, S.C., Sept. 18, 2012 /PRNewswire/ — Innocutis is pleased to announce the FDA approval of Nuvail(TM) (poly-ureaurethane, 16%) nail solution, a novel prescription product to help manage fragile, damaged or brittle nails with cracking or splitting, a condition medically referred to as “nail dystrophy.”

(Photo: http://photos.prnewswire.com/prnh/20120918/PH75611 )

Among the most common forms of nail dystrophy is Brittle Nail Syndrome (BNS), which often is referred to simply as “brittle nails.” Studies show that, on average, 20% of the population is affected by BNS and women are affected twice as often as men.(1)( )BNS may have various origins and is characterized by increased fragility of the nail plate. Patients who experience BNS, or other types of nail dystrophy, report their nails are painful and impair daily activities, which often negatively impacts their occupational abilities.(2)

Nuvail is formulated to mechanically support the damaged nail plate using a proprietary polymer blend that creates a strong adhesion to the nail surface, forming a breathable barrier while protecting and strengthening the nail. This breathable barrier allows for oxygen transfer to the nail plate while blocking water absorption therefore preventing the wet-dry cycle that leads to damaged nails. Daily application of Nuvail also protects the nail from harm caused by work activity such as direct abrasion and friction. The clinical benefits of Nuvail have recently been documented in a peer-reviewed clinical study published by the Journal of Drugs in Dermatology(3).

“Innocutis is proud and excited to introduce Nuvail as a unique and innovative breakthrough in the treatment and protection of damaged and dystrophic nails. For the first time, patients will have a nail treatment that allows the nail to breathe but is still non water-soluble and is able to protect the nail from the impact of moisture and friction,” said Jonathan Alba, Innocutis Chief Operating Officer.

Nuvail is available at all major retail pharmacies and can be purchased by prescription only in a 15ml bottle. For more information about Nuvail or to help locate a physician near you please visit http://nuvail-rx.com/physician-finder/

About Innocutis:

Innocutis is a pharmaceutical and medical device company specializing in the development and commercialization of therapies focused on medical treatments of dermatological conditions. We believe our focus on dermatologic conditions sets us apart as a company that understands the growing needs of the dermatology specialty. Our commitment is to be best-in-class in skin-related therapies, providing clinicians with improved solutions for the management of daily challenges experienced in their practice.

References:

(1) Lubach D, Cohrs W, Wurzinger R. Incidence of brittle nails. Dermatologica 1986; 172:144-7.

(2) Scher RK. Brittle nails. Int J Dermatol 1989;28:515-6

(3) Nasir A, Goldstein B, van Cleeff M, Swick L. Clinical evaluation of safety and efficacy of a new topical treatment for onycomycosis. J Drugs Dermatol. 2011; 10(10): 1186-91.

www.innocutis.com

http://nuvail-rx.com/

Contact:

Chuck Jenkins
Vice President of Sales & Marketing
Ph: 800-499-4468
inquiry@innocutis.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Innocutis


Source: PR Newswire